{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:47:39Z","timestamp":1788378459281,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ctrv.2025.102900","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:08:21Z","timestamp":1739182101000},"page":"102900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians"],"prefix":"10.1016","volume":"134","author":[{"given":"Enrique","family":"Grande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102900_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2025.102900_b0010","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.ctrv.2025.102900_b0015","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.21037\/tau-20-1472","article-title":"Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review","volume":"10","author":"Giudici","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0025","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: bladder cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"10.1016\/j.ctrv.2025.102900_b0030","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2217\/fon-2023-0298","article-title":"Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis","volume":"20","author":"Kearney","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0045","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v5.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.ctrv.2025.102900_b0050","unstructured":"Tecentriq (atezolizumab). Summary of product characteristics. Roche Registration GmbH; 2024."},{"key":"10.1016\/j.ctrv.2025.102900_b0055","unstructured":"Keytruda (pembrolizumab). Prescribing information. Merck & Co., Kenilworth, NJ, USA; 2024."},{"key":"10.1016\/j.ctrv.2025.102900_b0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2024.02.010","article-title":"The overall survival benefit in EV-302: is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma?","volume":"7","author":"Benjamin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMe2400311","article-title":"Enfortumab vedotin and pembrolizumab - a new perspective on urothelial cancer","volume":"390","author":"Niegisch","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euf.2024.03.005","article-title":"Front-line platinum continues to have a role in advanced bladder cancer","volume":"10","author":"Vogl","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2025.102900_b0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0095","doi-asserted-by":"crossref","unstructured":"Grande E, Birtle AJ, Kamat AM. Re: Thomas Powles, Begona Perez-Valderrama, Shilpa Gupta, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390:875-88. Eur Urol. 2024;86:e152-e3.","DOI":"10.1016\/j.eururo.2024.06.022"},{"key":"10.1016\/j.ctrv.2025.102900_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103725","article-title":"The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria","volume":"9","author":"Apolo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2025.102900_b0105","article-title":"Pairing the right individual with the right regimen: patient selection criteria in the treatment of advanced urothelial carcinoma","author":"Benjamin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2073","article-title":"Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: analysis of the UNITE study","volume":"35","author":"Jindal","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","article-title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","volume":"25","author":"Bamias","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0125","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0130","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0135","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0140","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.508","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102238","article-title":"Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study","volume":"22","author":"Grivas","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2025.102900_b0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.605","article-title":"Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC) receiving avelumab first-line maintenance (1LM) in the US","volume":"42","author":"Moon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0160","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","article-title":"Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \u201creal world\u201d experience","volume":"21","author":"Bakaloudi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2025.102900_b0165","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/iju.15473","article-title":"J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan","volume":"31","author":"Kikuchi","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1403120","article-title":"Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program","volume":"14","author":"Park","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0175","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment. Eur","author":"Barthelemy","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0180","article-title":"READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Dig Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0185","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0190","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2023.10.107","article-title":"Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial","volume":"34","author":"van der Heijden","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0195","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/fon-2022-0767","article-title":"Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients","volume":"19","author":"Grivas","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-023-00765-8","article-title":"Patient preferences in the treatment of genitourinary cancers","volume":"20","author":"Benjamin","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0210","article-title":"Patient preferences for first-line treatment of locally advanced or metastatic urothelial carcinoma: an application of multidimensional thresholding","author":"Apolo","year":"2024","journal-title":"Patient"},{"key":"10.1016\/j.ctrv.2025.102900_b0215","unstructured":"Padcev (enfortumab vedotin-ejfv). Prescribing information. Astellas Pharma US, Inc.; 2023."},{"key":"10.1016\/j.ctrv.2025.102900_b0220","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.23.00987","article-title":"Combinations, sequencing, and the contribution of components: new frontline standards for metastatic urothelial carcinoma","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4503","article-title":"Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0230","article-title":"Neurotoxicity caused by the treatment with platinum analogues","volume":"2011","author":"Amptoulach","year":"2011","journal-title":"Chemother Res Pract"},{"key":"10.1016\/j.ctrv.2025.102900_b0235","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/gfw338","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Malyszko","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ctrv.2025.102900_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102203","article-title":"Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis","volume":"79","author":"Dillard","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ctrv.2025.102900_b0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4516","article-title":"Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial","volume":"41","author":"Bellmunt","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0250","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2022.07.1838","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): results from patients with \u226512 mo of treatment in JAVELIN Bladder 100","volume":"33","author":"Aragon-Ching","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104420","article-title":"The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies","volume":"200","author":"Daher","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2025.102900_b0260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.euf.2024.05.012","article-title":"Toxicities of novel agents for the treatment of advanced bladder cancer","volume":"10","author":"McInerney","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2025.102900_b0265","unstructured":"ClinicalTrials.gov. Peripheral neuropathy in patients receiving enfortumab vedotin and pembrolizumab as first line treatment for metastatic or locally advanced urothelial carcinoma (P-EVOLUTION). https:\/\/clinicaltrials.gov\/study\/NCT06657157."},{"key":"10.1016\/j.ctrv.2025.102900_b0270","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4502","article-title":"Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0275","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0280","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.581","article-title":"Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0285","doi-asserted-by":"crossref","unstructured":"Powles T, Gupta S, Sridhar S, Bellmunt J, Tyroller K, Hoffman J, Grivas P. Avelumab first-line maintenance (1LM) in advanced urothelial carcinoma (aUC): analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in older patients (pts) from the JAVELIN Bladder 100 trial. Eur Urol Open Sci. 2024;69:317-8. Abstract P251.","DOI":"10.1016\/S2666-1683(24)01369-7"},{"key":"10.1016\/j.ctrv.2025.102900_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2047","article-title":"Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma","volume":"35","author":"Bedke","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0295","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.medj.2024.04.006","article-title":"Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: what is left behind?","volume":"5","author":"Bellmunt","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0300","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0305","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0310","article-title":"Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC): results of a physician survey in 5 European countries (Eu5)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0315","doi-asserted-by":"crossref","first-page":"S1207","DOI":"10.1016\/j.annonc.2023.09.1020","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)","volume":"34","author":"Gupta","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.102900_b0325","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0330","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ctrv.2025.102900_b0335","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3233\/BLC-160047","article-title":"Obesity and outcomes in patients with metastatic urothelial carcinoma","volume":"2","author":"Leiter","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ctrv.2025.102900_b0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.600","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI)","volume":"42","author":"Aragon-Ching","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0345","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0350","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0355","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/cncr.28146","article-title":"Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy","volume":"119","author":"Galsky","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102900_b0360","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.eururo.2016.09.042","article-title":"Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC)","volume":"71","author":"Necchi","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0365","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4563","article-title":"Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC): subgroup analyses results from EV-302, a phase 3 global study","volume":"42","author":"van der Heijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0370","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2023.03.030","article-title":"Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial","volume":"84","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.102900_b0375","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4566","article-title":"Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden","volume":"42","author":"Bellmunt","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0385","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4509","article-title":"Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node\u2013only metastatic urothelial carcinoma from the CheckMate 901 trial","volume":"42","author":"Galsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0390","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0395","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4567","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes","volume":"42","author":"Loriot","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0400","article-title":"Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: analysis of the UNITE study","volume":"42","author":"Jindal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0405","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2024.05.011","article-title":"Therapies after progression on enfortumab vedotin and pembrolizumab: navigating second-line options for metastatic urothelial carcinoma in the new treatment landscape","volume":"10","author":"Brown","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2025.102900_b0410","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4560","article-title":"Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: exploratory analyses from JAVELIN Bladder 100","volume":"40","author":"Bellmunt","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0415","article-title":"Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study","volume":"42","author":"Nizam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0420","doi-asserted-by":"crossref","unstructured":"Carson K, Mahmoudpour H, Ike C, Monzon S, Fragkogianni S, Ferrer J, Kearney M. Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la\/mUC): treatment (tx) patterns and real-world (rw) outcomes in the US. Ann Oncol. 2023;34:S1215-6. Abstract 2387P.","DOI":"10.1016\/j.annonc.2023.09.1036"},{"key":"10.1016\/j.ctrv.2025.102900_bib491","unstructured":"Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, et al. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. Ann Oncol. 2025 Feb 7:S0923-7534(25)00015-8. Epub ahead of print."},{"key":"10.1016\/j.ctrv.2025.102900_b0430","unstructured":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors [news release]. April 5, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"10.1016\/j.ctrv.2025.102900_b0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0440","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0445","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102900_b0450","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5489\/cuaj.8946","article-title":"2024 CUA-GUMOC Expert Report: management of unresectable locally advanced and metastatic urothelial carcinoma","volume":"18","author":"Stecca","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ctrv.2025.102900_b0455","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102900_b0460","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Klumper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0465","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102900_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102900_b0475","article-title":"Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) in the United States (US)","volume":"19","author":"Ike","year":"2023","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ctrv.2025.102900_b0480","article-title":"Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.102900_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1412292","article-title":"Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial","volume":"15","author":"You","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2025.102900_b0490","article-title":"Cost-effectiveness analysis in the new era of treatment strategies in metastatic urothelial carcinoma based on Checkmate-901 and EV302\/KEYNOTE-A39","author":"Rieger","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:26:10Z","timestamp":1762291570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":98,"alternative-id":["S0305737225000222"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102900","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102900"}}